MA28730B1 - Composes et methodes de traitement de la dyslipidemie - Google Patents

Composes et methodes de traitement de la dyslipidemie

Info

Publication number
MA28730B1
MA28730B1 MA29596A MA29596A MA28730B1 MA 28730 B1 MA28730 B1 MA 28730B1 MA 29596 A MA29596 A MA 29596A MA 29596 A MA29596 A MA 29596A MA 28730 B1 MA28730 B1 MA 28730B1
Authority
MA
Morocco
Prior art keywords
compounds
dyslipidemia
treatment methods
methods
formula
Prior art date
Application number
MA29596A
Other languages
English (en)
Inventor
Xinchao Chen
Christopher Lawrence Cioffi
Sean Richard Dinn
Ana Maria Escribano
Maria Carmen Fernandez
Todd Fields
Robert Jason Herr
Nathan Bryan Mantlo
De La Nava Eva Maria Martin
Ana Isabel Mateo-Herranz
Saravanan Parthasarathy
Xiaodong Wang
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35056992&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA28730(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA28730B1 publication Critical patent/MA28730B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MA29596A 2004-06-24 2006-12-29 Composes et methodes de traitement de la dyslipidemie MA28730B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US58270804P 2004-06-24 2004-06-24
US62724104P 2004-11-12 2004-11-12
US66486205P 2005-03-24 2005-03-24

Publications (1)

Publication Number Publication Date
MA28730B1 true MA28730B1 (fr) 2007-07-02

Family

ID=35056992

Family Applications (2)

Application Number Title Priority Date Filing Date
MA29595A MA28729B1 (fr) 2004-06-24 2006-12-29 Composés et procédés destinés à traiter la dyslipidémie
MA29596A MA28730B1 (fr) 2004-06-24 2006-12-29 Composes et methodes de traitement de la dyslipidemie

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA29595A MA28729B1 (fr) 2004-06-24 2006-12-29 Composés et procédés destinés à traiter la dyslipidémie

Country Status (26)

Country Link
US (3) US20080269284A1 (fr)
EP (3) EP1761521A1 (fr)
JP (2) JP2008504266A (fr)
KR (1) KR20070041452A (fr)
CN (1) CN1972932B (fr)
AT (1) ATE528304T1 (fr)
AU (2) AU2005267436A1 (fr)
BR (2) BRPI0512523A (fr)
CA (2) CA2570688A1 (fr)
CR (1) CR8831A (fr)
CY (1) CY1112124T1 (fr)
DK (1) DK1761522T3 (fr)
EA (2) EA200700119A1 (fr)
EC (2) ECSP067095A (fr)
ES (1) ES2372291T3 (fr)
HR (1) HRP20110761T1 (fr)
IL (2) IL180276A0 (fr)
MA (2) MA28729B1 (fr)
MX (2) MXPA06014716A (fr)
NO (2) NO20070470L (fr)
NZ (1) NZ550978A (fr)
PL (1) PL1761522T3 (fr)
PT (1) PT1761522E (fr)
RS (1) RS52064B (fr)
SI (1) SI1761522T1 (fr)
WO (2) WO2006012093A1 (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004023100D1 (de) * 2003-10-08 2009-10-22 Lilly Co Eli Verbindungen und verfahren zur behandlung von dyslipidemie
JP2007530550A (ja) * 2004-03-26 2007-11-01 イーライ リリー アンド カンパニー 異脂肪血症を治療するための化合物および方法
UA90269C2 (ru) 2004-04-02 2010-04-26 Мицубиси Танабе Фарма Корпорейшн Тетрагидрохинолиновые производные и способ их получения
EA200700119A1 (ru) 2004-06-24 2007-10-26 Эли Лилли Энд Компани Соединения и способы лечения дислипидемии
WO2007107843A1 (fr) * 2006-03-22 2007-09-27 Pfizer Products Inc. Procédés de traitement avec des inhibiteurs de la cetp
UY30244A1 (es) 2006-03-30 2007-11-30 Tanabe Seiyaku Co Un proceso para preparar derivados de tetrahidroquinolina
EP2061767B1 (fr) 2006-08-08 2014-12-17 Sanofi Imidazolidin-2,4-diones arylaminoaryl-alkyl-substituées, procédé de fabrication, médicaments les contenant et leur utilisation
DE102007005045B4 (de) 2007-01-26 2008-12-18 Sanofi-Aventis Phenothiazin Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP2157190B1 (fr) * 2007-05-17 2017-05-03 EA Pharma Co., Ltd. Procédé de mesure de l'activité d'une enzyme modifiée par un lipide
EP2025674A1 (fr) 2007-08-15 2009-02-18 sanofi-aventis Tetrahydronaphthaline substituée, son procédé de fabrication et son utilisation en tant que médicament
DE102007054497B3 (de) 2007-11-13 2009-07-23 Sanofi-Aventis Deutschland Gmbh Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung
UY31968A (es) 2008-07-09 2010-01-29 Sanofi Aventis Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos
WO2010068601A1 (fr) 2008-12-08 2010-06-17 Sanofi-Aventis Hydrate de fluoroglycoside hétéroaromatique cristallin, ses procédés de fabrication, ses procédés d'utilisation et compositions pharmaceutiques le contenant
TWI450896B (zh) * 2009-06-30 2014-09-01 Lilly Co Eli 反式－４－〔〔（５ｓ）－５－〔〔〔３，５－雙（三氟甲基）苯基〕甲基〕（２－甲基－２ｈ－四唑－５－基）胺基〕－２，３，４，５－四氫－７，９－二甲基－１ｈ－１－苯并氮呯－１－基〕甲基〕－環己基羧酸
KR20120060207A (ko) 2009-08-26 2012-06-11 사노피 신규한 결정성 헤테로방향족 플루오로글리코시드 수화물, 이들 화합물을 포함하는 약제 및 이들의 용도
EP2582709B1 (fr) 2010-06-18 2018-01-24 Sanofi Dérivés d'azolopyridin-3-one en tant qu'inhibiteurs de lipases et de phospholipases
EP2683699B1 (fr) 2011-03-08 2015-06-24 Sanofi Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
WO2012120056A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés oxathiazine tétra-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
WO2012120058A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés d'oxathiazine substitués par des groupes benzyle ou hétérométhylène, leur procédé de production, leur utilisation comme médicament ainsi que produits pharmaceutiques les contenant et leur utilisation
EP2766349B1 (fr) 2011-03-08 2016-06-01 Sanofi Dérivés d'oxathiazine substitués par des carbocycles ou des hétérocycles, leur procédé de préparation, médicaments contenant ces composés et leur utilisation
EP2683702B1 (fr) 2011-03-08 2014-12-24 Sanofi Nouveaux dérivés de phényle-oxathiazine substitués, leur procédé de fabrication, médicament contenant ces liaisons et son utilisation
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120051A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés benzyl-oxathiazine substitués avec adamantane ou noradamantane, médicaments contenant ces composés et leur utilisation
US8895547B2 (en) 2011-03-08 2014-11-25 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
EP2683704B1 (fr) 2011-03-08 2014-12-17 Sanofi Dérivés oxathiazine ramifiés, procédé pour leur préparation, utilisation en tant que médicament, agents pharmaceutiques contenant ces dérivés et leur utilisation
SG10201605304VA (en) * 2011-07-08 2016-08-30 Novartis Ag Method of treating atherosclerosis in high triglyceride subjects
EP2567959B1 (fr) 2011-09-12 2014-04-16 Sanofi Dérivés d'amide d'acide 6-(4-hydroxy-phényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
DK2860175T3 (da) * 2012-06-11 2018-01-29 Tacurion Fremgangsmåde til fremstilling af 4,4,7-trifluor-1,2,3,4-tetrahydro-5h-1-benzazepin-forbindelse og intermediat til syntese deraf
WO2014012401A1 (fr) * 2012-07-16 2014-01-23 上海恒瑞医药有限公司 Dérivé benzo-hétérocyclique à sept chaînons, son procédé de préparation et ses applications médicales
MX369471B (es) * 2014-02-05 2019-11-08 Dezima Pharma B V Inhibidor de proteina de transferencia del ester de colesterilo (cetp) y composiciones farmaceuticas que comprenden el inhibidor para uso en el tratamiento o prevencion de enfermedades cardiovasculares.
CN103833637B (zh) * 2014-03-31 2016-01-06 武汉武药制药有限公司 一种制备依塞曲匹（Evacetrapib）中间体的方法
JP6549735B2 (ja) 2015-06-09 2019-07-24 アッヴィ・インコーポレイテッド 核内受容体調節剤
WO2016198908A1 (fr) 2015-06-09 2016-12-15 Abbvie Inc. Modulateurs des récepteurs nucléaires ror
AU2019318209B2 (en) 2018-08-10 2025-09-25 Diapin Therapeutics, Llc Tri-peptides and treatment of metabolic, cardiovascular and inflammatory disorders
WO2024249901A2 (fr) * 2023-06-01 2024-12-05 Nico Therapeutics, Inc. Composés, compositions et procédés
CN117263810B (zh) * 2023-09-19 2026-01-27 上海凌凯科技股份有限公司 还原硝基苯制备苯胺类化合物以及选择性碘代苯胺类化合物的方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2402506A1 (fr) * 1977-09-09 1979-04-06 Guelennec Emile Le Cisaille pour la decoupe de ferrailles de grandes dimensions
US6147089A (en) * 1998-09-17 2000-11-14 Pfizer Inc. Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
GT199900147A (es) * 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
HN2000000203A (es) * 1999-11-30 2001-06-13 Pfizer Prod Inc Procedimiento para la obtencion de 1,2,3,4-tetrahidroquinolinas 4-carboxiamino-2- sustituidas.
CO5271716A1 (es) * 1999-11-30 2003-04-30 Pfizer Prod Inc Cristales de 4- carboxamino 1,2,3,4-tetrahidroquinolina 2- sustituida
MXPA03009935A (es) * 2001-04-30 2004-01-29 Pfizer Prod Inc Metodos e intermedios para preparar inhibidores 4-aminoquinolina de cetp.
US7332514B2 (en) 2002-08-30 2008-02-19 Japan Tobacco Inc. Dibenzylamine compound and medicinal use thereof
WO2004032848A2 (fr) 2002-10-04 2004-04-22 Millennium Pharmaceuticals, Inc. Antagonistes vis-a-vis du recepteur pgd2 pour le traitement de maladies inflammatoires
EP1601655A2 (fr) 2003-03-04 2005-12-07 Takasago International Corporation Procede de production d'amines optiquement actives
US20040204450A1 (en) * 2003-03-28 2004-10-14 Pfizer Inc Quinoline and quinoxaline compounds
DE602004023100D1 (de) 2003-10-08 2009-10-22 Lilly Co Eli Verbindungen und verfahren zur behandlung von dyslipidemie
JP2007530550A (ja) 2004-03-26 2007-11-01 イーライ リリー アンド カンパニー 異脂肪血症を治療するための化合物および方法
UA90269C2 (ru) * 2004-04-02 2010-04-26 Мицубиси Танабе Фарма Корпорейшн Тетрагидрохинолиновые производные и способ их получения
EA200700119A1 (ru) 2004-06-24 2007-10-26 Эли Лилли Энд Компани Соединения и способы лечения дислипидемии
US7700774B2 (en) 2004-12-20 2010-04-20 Dr. Reddy's Laboratories Ltd. Heterocyclic compounds and their pharmaceutical compositions
TWI450896B (zh) * 2009-06-30 2014-09-01 Lilly Co Eli 反式－４－〔〔（５ｓ）－５－〔〔〔３，５－雙（三氟甲基）苯基〕甲基〕（２－甲基－２ｈ－四唑－５－基）胺基〕－２，３，４，５－四氫－７，９－二甲基－１ｈ－１－苯并氮呯－１－基〕甲基〕－環己基羧酸

Also Published As

Publication number Publication date
NO20070468L (no) 2007-03-12
WO2006012093A1 (fr) 2006-02-02
CN1972932B (zh) 2011-06-29
WO2006002342A1 (fr) 2006-01-05
BRPI0512516A (pt) 2008-03-11
US20070244095A1 (en) 2007-10-18
CY1112124T1 (el) 2015-11-04
MXPA06014706A (es) 2007-03-12
BRPI0512523A (pt) 2008-03-11
CA2570673A1 (fr) 2006-01-05
EA200700119A1 (ru) 2007-10-26
EP1761522B1 (fr) 2011-10-12
RS52064B (sr) 2012-06-30
IL180276A0 (en) 2007-07-04
DK1761522T3 (da) 2012-01-02
MXPA06014716A (es) 2007-03-12
EA200700120A1 (ru) 2007-06-29
HRP20110761T1 (hr) 2011-11-30
CR8831A (es) 2008-11-13
HK1104528A1 (en) 2008-01-18
US20100204207A1 (en) 2010-08-12
CN1972932A (zh) 2007-05-30
JP4836945B2 (ja) 2011-12-14
SI1761522T1 (sl) 2012-02-29
ECSP067098A (es) 2007-01-26
CA2570688A1 (fr) 2006-02-02
EP1761521A1 (fr) 2007-03-14
JP2008504277A (ja) 2008-02-14
NO20070470L (no) 2007-03-26
EA012585B1 (ru) 2009-10-30
AU2005267436A1 (en) 2006-02-02
EP2479175A1 (fr) 2012-07-25
AU2005258241A1 (en) 2006-01-05
ECSP067095A (es) 2007-01-26
ES2372291T3 (es) 2012-01-18
US7786108B2 (en) 2010-08-31
IL180277A0 (en) 2007-07-04
IL180277A (en) 2011-08-31
AU2005258241B2 (en) 2011-08-25
ATE528304T1 (de) 2011-10-15
EP1761522A1 (fr) 2007-03-14
US20080269284A1 (en) 2008-10-30
NZ550978A (en) 2010-08-27
MA28729B1 (fr) 2007-07-02
CA2570673C (fr) 2013-01-29
JP2008504266A (ja) 2008-02-14
PT1761522E (pt) 2011-12-21
KR20070041452A (ko) 2007-04-18
PL1761522T3 (pl) 2012-03-30

Similar Documents

Publication Publication Date Title
MA28730B1 (fr) Composes et methodes de traitement de la dyslipidemie
LTC1781298I2 (lt) Farmacinės kompozicijos, turinčios benzoksazino, skirtos respiracinių ligų gydymui
CY1110398T1 (el) Ενωσεις για την αγωγη της δυσλιπιδαιμιας
CY1109998T1 (el) Ενδυναμωτες υποδοχεων γλουταμινικου
DK1853602T3 (da) Kemiske forbindelser
CY1108275T1 (el) Χημικες ενωσεις
GEP20084452B (en) Sulfonamide derivatives for the treatment of diseases
NO20075111L (no) Farmasoytisk sammensetning
EA200802007A1 (ru) Соединения, потенцирующие рецептор амра, и применение указанных соединений в медицине
MA28600B1 (fr) Dérivés de dioxyde d'oxazolobenzoisothiazole substitués, procédé de production et utilisation de ceux-ci
DK1937633T3 (da) Biphenyloxyeddikesyrederivater til behandling af respiratoriske sygdomme
DK1940409T3 (da) Nye lægemiddelkombinationer til behandling af åndedrætssygdomme
DK1730144T3 (da) Substituerede 1,4,8-triazaspiro[4.5]decan-2-on-forbindelser
DK1856070T3 (da) Nye lægemidler til behandling af luftvejssygdomme
UY29999A1 (es) "n-pirazinil-fenilsulfonamidas, procedimientos y compuestos intemedios utilizados en su preparacion, composiciones farmaceuticas que las contienen y aplicaciones"
EA200701856A1 (ru) Тетрагидропиридоазепин-8-оны и родственные соединения для лечения шизофрении
EA200701178A1 (ru) Новые соединения нафталина, способ их получения и фармацевтические композиции, содержащие их
EA200701177A1 (ru) Новые соединения нафталина, способ их получения и фармацевтические композиции, содержащие их
FR2894579B1 (fr) Derives diaryltriazolmethylamine, leur preparation et leur application en therapeutique.
EA200701813A1 (ru) Новые амидозамещенные 6-фенилфенантридины
PL1853220T5 (pl) Sposób wytwarzania pastylek zawierających NLPZ, ich kompozycje, ich zastosowanie medyczne
EA201390619A1 (ru) 3-замещенные 6-(пиридинилметокси)пирролопиридиновые соединения
SE0400575D0 (sv) A novel pharmacentical composition for the treatment of skin conditions